AIkido Pharma (NASDAQ:AIKI – Get Free Report) and ASA Gold and Precious Metals (NYSE:ASA – Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Institutional and Insider Ownership
10.9% of AIkido Pharma shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 1.7% of ASA Gold and Precious Metals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for AIkido Pharma and ASA Gold and Precious Metals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AIkido Pharma | 0 | 0 | 0 | 0 | 0.00 |
| ASA Gold and Precious Metals | 0 | 0 | 1 | 0 | 3.00 |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AIkido Pharma | N/A | N/A | -$7.17 million | ($3.88) | -0.63 |
| ASA Gold and Precious Metals | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares AIkido Pharma and ASA Gold and Precious Metals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AIkido Pharma | N/A | -18.21% | -16.94% |
| ASA Gold and Precious Metals | N/A | N/A | N/A |
Risk & Volatility
AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, ASA Gold and Precious Metals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Summary
ASA Gold and Precious Metals beats AIkido Pharma on 4 of the 7 factors compared between the two stocks.
About AIkido Pharma
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
About ASA Gold and Precious Metals
ASA Gold and Precious Metals Limited is a publicly owned investment manager. The firm invests in the public equity markets across the globe. It primarily invests in stocks of companies engaged in the exploration, mining or processing of gold, silver, platinum, diamonds, or other precious minerals. It also invests in exchange traded funds. The firm employs fundamental analysis with a bottom-up approach to create its portfolios. The firm obtains external research to complement its in-house research. The firm is focused on covering the metals and mining sector. This record reflects the investment preferences or overall investment strategy of ASA Gold and Precious Metals Limited. ASA Gold and Precious Metals Limited was founded in 1958 and is based in Portland, Maine.
Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
